Derek Archila
Stock Analyst at Wells Fargo
(3.71)
# 732
Out of 4,945 analysts
181
Total ratings
47.86%
Success rate
7.72%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.77 | +288.60% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $1.71 | +16.96% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $191.15 | +54.33% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.49 | +235.57% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $18.86 | +37.89% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $7.09 | +125.67% | 7 | Aug 7, 2025 | |
| INCY Incyte | Upgrades: Overweight | $67 → $89 | $85.85 | +3.67% | 9 | Aug 6, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $741 → $756 | $646.60 | +16.92% | 12 | Jul 31, 2025 | |
| ALMS Alumis | Initiates: Overweight | $17 | $4.42 | +284.62% | 1 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $91 → $129 | $97.86 | +31.82% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $40.74 | +30.09% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $25 | $5.15 | +385.44% | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $26.58 | +9.10% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $11.69 | +53.98% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $10.57 | +136.52% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.44 | +125.23% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.81 | +728.73% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $38.49 | -6.47% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $20.74 | +145.96% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $13.94 | +0.43% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.92 | +129.59% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $15.89 | +183.20% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $2.33 | +415.02% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.47 | +591.64% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.85 | +285.96% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $24.99 | +48.06% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.60 | +284.62% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.94 | +930.93% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.02 | +347.76% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.08 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $32.31 | +497.34% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $75.33 | -45.57% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.90 | +973.83% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.94 | +503.54% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.36 | +565.14% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.40 | +3,471.43% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $20.11 | +153.61% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $23.66 | +271.94% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.96 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.21 | - | 2 | Aug 3, 2017 |
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.77
Upside: +288.60%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.71
Upside: +16.96%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $191.15
Upside: +54.33%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.49
Upside: +235.57%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $18.86
Upside: +37.89%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $7.09
Upside: +125.67%
Incyte
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $85.85
Upside: +3.67%
argenx SE
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $646.60
Upside: +16.92%
Alumis
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.42
Upside: +284.62%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $97.86
Upside: +31.82%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $40.74
Upside: +30.09%
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $5.15
Upside: +385.44%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $26.58
Upside: +9.10%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $11.69
Upside: +53.98%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $10.57
Upside: +136.52%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.44
Upside: +125.23%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.81
Upside: +728.73%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $38.49
Upside: -6.47%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $20.74
Upside: +145.96%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $13.94
Upside: +0.43%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.92
Upside: +129.59%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $15.89
Upside: +183.20%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $2.33
Upside: +415.02%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.47
Upside: +591.64%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.85
Upside: +285.96%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $24.99
Upside: +48.06%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.60
Upside: +284.62%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.94
Upside: +930.93%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.02
Upside: +347.76%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.08
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $32.31
Upside: +497.34%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $75.33
Upside: -45.57%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.90
Upside: +973.83%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.94
Upside: +503.54%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.36
Upside: +565.14%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.40
Upside: +3,471.43%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $20.11
Upside: +153.61%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $23.66
Upside: +271.94%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.96
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $17.21
Upside: -